NCT07091279View on ClinicalTrials.gov

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

December 31, 2028

Conditions
Autism Spectrum DisorderChallenging BehaviourAggressionSevere Disruptive Behaviour DisordersSelf-injury
Interventions
DRUG

Propranolol

Propranolol, oral, titrated in weekly increments from 10 mg TID to a maximum of 200 mg TID (total daily dose: 30 mg to 600 mg at 8 weeks), based on tolerability. Participants will continue at the highest tolerated dose for additional 4 weeks. Target doses: 10 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg TID.

DRUG

Placebo

Placebo for Propranolol

Trial Locations (2)

10314

RECRUITING

New York State Institute for Basic Research (IBR), Staten Island

10605

RECRUITING

Center for Autism and the Developing Brain, White Plains

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

New York State Institute for Basic Research

OTHER_GOV

lead

Jeremy Veenstra-vanderweele

OTHER

NCT07091279 - Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism | Biotech Hunter | Biotech Hunter